Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa Ford

Showing results (21-30 of 47) with videos related to

Pageof 5
Sort By:
Epilepsy Research|April 15, 2014
Pharmacokinetics of topiramate in patients with renal impairment, end-stage renal disease undergoing hemodialysis, or hepatic impairmentPrasarn Manitpisitkul, Christopher R Curtin, Kevin Shalayda, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|January 1, 2008
Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extensionAndreas Tzimos, Viktor Samokhvalov, Michelle Kramer, et al.
Biological Psychiatry|July 3, 2007
Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled studyStephen R Marder, Michelle Kramer, Lisa Ford, et al.
Advances in Clinical Chemistry|March 26, 2022
Clinical metabolomics for inborn errors of metabolismLisa Ford, Matthew Mitchell, Jacob Wulff, et al.
Pediatric Neurology|February 18, 2010
Cognitive effects of topiramate in migraine patients aged 12 through 17 yearsGahan J Pandina, Seth Ness, Elena Polverejan, et al.
Epilepsia|November 1, 2025
A randomized, double-blind, placebo-controlled, time-to-event study of the efficacy and safety of JNJ-40411813 in combination with levetiracetam or brivaracetam in patients with focal onset seizuresJacqueline French, Magdalena Bosak, Wesley T Kerr, et al.
Journal of Alzheimer'S Disease : JAD|September 25, 2015
Age-Stratified Prevalence of Mild Cognitive Impairment and Dementia in European Populations: A Systematic ReviewMyriam Alexander, Gayan Perera, Lisa Ford, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|May 23, 2021
The effects of JNJ-39393406 a positive allosteric nicotine modulator on mood and cognition in patients with unipolar depression: A double-blind, add-on, placebo-controlled trialMichael Davidson, Linda Levi, Jinyoung Park, et al.
Journal of Clinical Psychopharmacology|September 9, 2024
Lack of Efficacy of JNJ-18038683 on Cognitive Impairment in Patients With Stable Bipolar DisorderMahdi Arshadi, Ahmed Z Elmaadawi, Suhayl Nasr, et al.
Plos One|April 8, 2021
Global biochemical analysis of plasma, serum and whole blood collected using various anticoagulant additivesAdam D Kennedy, Lisa Ford, Bryan Wittmann, et al.
Pageof 5

Showing results (21-30 of 47) with videos related to

Sort By:
Pageof 5
Epilepsy Research|April 15, 2014
Pharmacokinetics of topiramate in patients with renal impairment, end-stage renal disease undergoing hemodialysis, or hepatic impairmentPrasarn Manitpisitkul, Christopher R Curtin, Kevin Shalayda, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|January 1, 2008
Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extensionAndreas Tzimos, Viktor Samokhvalov, Michelle Kramer, et al.
Biological Psychiatry|July 3, 2007
Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled studyStephen R Marder, Michelle Kramer, Lisa Ford, et al.
Advances in Clinical Chemistry|March 26, 2022
Clinical metabolomics for inborn errors of metabolismLisa Ford, Matthew Mitchell, Jacob Wulff, et al.
Pediatric Neurology|February 18, 2010
Cognitive effects of topiramate in migraine patients aged 12 through 17 yearsGahan J Pandina, Seth Ness, Elena Polverejan, et al.
Epilepsia|November 1, 2025
A randomized, double-blind, placebo-controlled, time-to-event study of the efficacy and safety of JNJ-40411813 in combination with levetiracetam or brivaracetam in patients with focal onset seizuresJacqueline French, Magdalena Bosak, Wesley T Kerr, et al.
Journal of Alzheimer'S Disease : JAD|September 25, 2015
Age-Stratified Prevalence of Mild Cognitive Impairment and Dementia in European Populations: A Systematic ReviewMyriam Alexander, Gayan Perera, Lisa Ford, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|May 23, 2021
The effects of JNJ-39393406 a positive allosteric nicotine modulator on mood and cognition in patients with unipolar depression: A double-blind, add-on, placebo-controlled trialMichael Davidson, Linda Levi, Jinyoung Park, et al.
Journal of Clinical Psychopharmacology|September 9, 2024
Lack of Efficacy of JNJ-18038683 on Cognitive Impairment in Patients With Stable Bipolar DisorderMahdi Arshadi, Ahmed Z Elmaadawi, Suhayl Nasr, et al.
Plos One|April 8, 2021
Global biochemical analysis of plasma, serum and whole blood collected using various anticoagulant additivesAdam D Kennedy, Lisa Ford, Bryan Wittmann, et al.
Pageof 5